1. Home
  2. PCSA vs FEBO Comparison

PCSA vs FEBO Comparison

Compare PCSA & FEBO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Processa Pharmaceuticals Inc.

PCSA

Processa Pharmaceuticals Inc.

N/A

Current Price

$2.89

Market Cap

8.0M

Sector

Health Care

ML Signal

N/A

Logo Fenbo Holdings Limited

FEBO

Fenbo Holdings Limited

N/A

Current Price

$1.06

Market Cap

11.8M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
PCSA
FEBO
Founded
2011
1993
Country
United States
Hong Kong
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.0M
11.8M
IPO Year
2012
2022

Fundamental Metrics

Financial Performance
Metric
PCSA
FEBO
Price
$2.89
$1.06
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$25.00
N/A
AVG Volume (30 Days)
31.1K
4.7K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
54.36
N/A
EPS
N/A
N/A
Revenue
$5,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.11
$0.61
52 Week High
$8.88
$1.48

Technical Indicators

Market Signals
Indicator
PCSA
FEBO
Relative Strength Index (RSI) 59.37 52.98
Support Level $0.21 $1.06
Resistance Level $3.80 $1.12
Average True Range (ATR) 0.30 0.03
MACD 0.10 -0.00
Stochastic Oscillator 85.38 71.83

Price Performance

Historical Comparison
PCSA
FEBO

About PCSA Processa Pharmaceuticals Inc.

Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).

About FEBO Fenbo Holdings Limited

Fenbo Holdings Ltd is a company engaged in producing premium personal care electric appliances, principally electrical hair styling products such as straighteners, curlers, trimmers, etc., and toy products to overseas markets. It manufactures and sells products such as Straightener, Mini Straightener, and Curling Iron.

Share on Social Networks: